MHY1485 activates mTOR and protects osteoblasts from dexamethasone

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Dexamethasone (Dex) is known to induce cytotoxic effects in osteoblasts.
• The mammalian target of rapamycin (mTOR) pathway plays a crucial role in cellular processes, including cell survival and proliferation.

Purpose of the Study:

• To investigate the potential protective effect of MHY1485, an mTOR activator, against dexamethasone-induced osteoblast death.
• To elucidate the specific mTOR complex (mTORC1 or mTORC2) involved in MHY1485's protective mechanism.

Main Methods:

• Utilized osteoblastic MC3T3-E1 cells and primary murine osteoblasts.
• Administered MHY1485 and dexamethasone, with and without mTOR inhibitors (OSI-027, rapamycin, RAD001) or shRNAs (mTOR, Raptor, Rictor).
• Assessed cell viability, apoptosis, and mitochondrial death pathway activation (depolarization, cyclophilin D-ANT-1 association, cytochrome C release).

Main Results:

• MHY1485 significantly reduced dexamethasone-induced cell death and apoptosis in osteoblasts.
• Inhibition of mTOR signaling abolished MHY1485's protective effect.
• Activation of mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2), was essential for MHY1485's anti-cytotoxic activity.
• MHY1485 inhibited dexamethasone-induced mitochondrial death pathway activation.

Conclusions:

• MHY1485 demonstrates significant osteoprotective effects against dexamethasone-induced cytotoxicity.
• The protective mechanism involves the activation of mTORC1 signaling.
• MHY1485's action is mediated through the inhibition of the mitochondrial death pathway, highlighting its therapeutic potential in conditions involving dexamethasone-induced bone damage.